Lifecome Biochemistry Co.,Ltd. (SHE:002868)
China · Delayed Price · Currency is CNY 18.85
+0.56 (3.06%)
Nov 5, 2026, 3:04 PM CST
Lifecome Biochemistry Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 424.5 | 487.96 | 610.68 | 489.93 | 308.72 | 343.29 |
Other Revenue | 28.62 | 28.62 | 38.69 | 17.07 | 21.14 | 20.09 |
| 453.12 | 516.58 | 649.37 | 507 | 329.85 | 363.39 | |
Revenue Growth | -22.81% | -20.45% | 28.08% | 53.71% | -9.23% | 17.93% |
Cost of Revenue | 392.99 | 500.69 | 756.06 | 611.75 | 381.36 | 311.55 |
Gross Profit | 60.12 | 15.89 | -106.69 | -104.74 | -51.51 | 51.84 |
Selling, General & Admin | 45.31 | 69.33 | 61.05 | 54.06 | 38.16 | 37.29 |
Research & Development | 18.64 | 25.6 | 35.56 | 27.53 | 21.82 | 24.82 |
Other Operating Expenses | 7.1 | 6.01 | 7.08 | 4.4 | 3.86 | 2.97 |
Operating Expenses | 70.64 | 99.39 | 104.06 | 87.26 | 65.19 | 65.8 |
Operating Income | -10.52 | -83.5 | -210.75 | -192 | -116.7 | -13.96 |
Interest Expense | -15.64 | -53.81 | -62.06 | -37.1 | -16.22 | -2.81 |
Interest & Investment Income | - | 4.62 | 9.4 | 11.55 | 0.18 | 0.83 |
Currency Exchange Gain (Loss) | 0.53 | 0.53 | 2.62 | -0.56 | 2.1 | -1.23 |
Other Non Operating Income (Expenses) | -15.89 | -0.66 | -0.04 | -1.31 | -0.23 | -0.13 |
EBT Excluding Unusual Items | -42.93 | -132.82 | -260.84 | -219.42 | -130.88 | -17.31 |
Impairment of Goodwill | - | - | -61.6 | -12.7 | - | - |
Gain (Loss) on Sale of Investments | - | - | - | - | -10.12 | -20.56 |
Gain (Loss) on Sale of Assets | 0.02 | 0.27 | 0.04 | -0.04 | - | 0.01 |
Asset Writedown | -2.75 | -3.04 | -110.39 | -12.15 | -6.25 | -0.22 |
Other Unusual Items | -4.27 | -3.27 | 4.64 | 3.42 | 13.14 | 5.73 |
Pretax Income | -49.93 | -138.85 | -428.15 | -240.89 | -134.11 | -32.35 |
Income Tax Expense | 0.26 | 0.45 | 17.83 | -18.28 | -11.39 | -5.91 |
Earnings From Continuing Operations | -50.2 | -139.31 | -445.98 | -222.62 | -122.72 | -26.44 |
Minority Interest in Earnings | 0.69 | 0.04 | 1.11 | 0.8 | 0.78 | 0.4 |
Net Income | -49.5 | -139.26 | -444.86 | -221.82 | -121.94 | -26.04 |
Net Income to Common | -49.5 | -139.26 | -444.86 | -221.82 | -121.94 | -26.04 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 154 | 155 | 156 | 154 | 154 | 153 |
Shares Outstanding (Diluted) | 154 | 155 | 156 | 154 | 154 | 153 |
Shares Change | -1.64% | -0.52% | 0.98% | -0.20% | 0.75% | -0.72% |
EPS (Basic) | -0.32 | -0.90 | -2.86 | -1.44 | -0.79 | -0.17 |
EPS (Diluted) | -0.32 | -0.90 | -2.86 | -1.44 | -0.79 | -0.17 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -187.29 | -154.88 | 16.35 | -651.3 | -146.15 | -322 |
Free Cash Flow Per Share | -1.22 | -1.00 | 0.10 | -4.23 | -0.95 | -2.10 |
Gross Margin | 13.27% | 3.08% | -16.43% | -20.66% | -15.62% | 14.27% |
Operating Margin | -2.32% | -16.16% | -32.45% | -37.87% | -35.38% | -3.84% |
Profit Margin | -10.93% | -26.96% | -68.51% | -43.75% | -36.97% | -7.17% |
Free Cash Flow Margin | -41.33% | -29.98% | 2.52% | -128.46% | -44.31% | -88.61% |
EBITDA | 82.8 | 11.34 | -113.88 | -122.73 | -52.61 | 19.91 |
EBITDA Margin | 18.27% | 2.20% | -17.54% | -24.21% | -15.95% | 5.48% |
D&A For EBITDA | 93.31 | 94.84 | 96.87 | 69.28 | 64.09 | 33.87 |
EBIT | -10.52 | -83.5 | -210.75 | -192 | -116.7 | -13.96 |
EBIT Margin | -2.32% | -16.16% | -32.45% | -37.87% | -35.38% | -3.84% |
Revenue as Reported | 106.91 | 516.58 | 649.37 | 507 | 329.85 | 363.39 |
Advertising Expenses | - | 0.09 | 0.36 | 0.44 | 0.8 | 2.03 |